Human Immunodeficiency Virus (HIV) Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$17995
Buy Report Download FREE Resources

Published: March 31, 2026 Report Code: GDHC338PIDR-7M-ST

Select Item

Explore the global HIV therapeutics market with GlobalData’s in-depth industry analysis covering HIV epidemiology, treatment landscape, pipeline therapies, antiretroviral innovations, PrEP trends, market forecasts, and competitive dynamics across the 7 major pharmaceutical markets. Analyze HIV market outlook through 2033, including current and future therapies, unmet needs, R&D strategies, annual therapy costs, pipeline assessment, and sales forecasts for marketed and late-stage products. Built on GlobalData’s proprietary pharma intelligence and supported by expert analyst insights, this report helps pharmaceutical companies, biotech firms, investors, and healthcare strategy teams benchmark competitors, identify commercial opportunities, and support long-term decision-making within the evolving HIV therapeutics market.

Report Value Proposition – Why This Matters for You

The HIV therapeutics market continues to evolve through advances in antiretroviral therapy (ART), long-acting injectable treatments, and pre-exposure prophylaxis (PrEP) innovations. Decades after HIV was first identified as the cause of acquired immunodeficiency syndrome (AIDS), the treatment landscape has become increasingly competitive, with new technologies improving disease management, patient adherence, and long-term outcomes.

This report helps you understand how epidemiology trends, treatment innovation, pipeline development, and competitive dynamics are shaping the global HIV market across the seven major pharmaceutical markets (7MM). In addition, it provides detailed analysis of current therapies, emerging products, unmet needs, market opportunities, and future commercial outlooks through 2033.

The report also delivers insight into therapy costs, sales forecasts, R&D strategies, pipeline positioning, and competitor benchmarking to support strategic planning, licensing decisions, commercial expansion, and investment evaluation.

Key Insights in the HIV Therapeutics Market

  • Covers the HIV therapeutics market across the 7 major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, and Japan).
  • Forecast period spans from 2023–2033.
  • Focuses specifically on HIV-1, the dominant strain across the covered markets.
  • Includes analysis of marketed products and Phase III pipeline therapies.
  • Long-acting injectables and once-daily single-tablet regimens continue reshaping HIV treatment approaches.
  • PrEP therapies are becoming increasingly important within the preventive care landscape.
  • The HIV market remains highly competitive with multiple established global pharmaceutical players.
  • Includes annual therapy cost analysis and sales forecasts by product.
  • Evaluates unmet needs, R&D strategies, and future treatment innovation opportunities.
  • Combines epidemiology, disease management, and commercial market intelligence into a comprehensive industry assessment.

Scope

What You Will Learn

  • HIV therapeutics market size and forecast outlook through 2033

  • HIV epidemiology, disease overview, and pathophysiology trends

  • Current antiretroviral therapy (ART) landscape and treatment evolution

  • Long-acting injectable therapy and PrEP market developments

  • Pipeline assessment and late-stage therapy analysis

  • Annual therapy costs and product-level sales forecasts

  • Competitive landscape and strategic benchmarking

  • R&D strategies and innovation trends influencing the HIV market

  • Unmet needs and future commercial opportunities

  • Market drivers shaping HIV therapeutics adoption and growth

Target Buyers for This Report

This report may support decision-making for:

  • Pharmaceutical and biotech companies

  • HIV drug developers and infectious disease specialists

  • Healthcare investors and private equity firms

  • Licensing and business development teams

  • Commercial strategy and market intelligence professionals

  • Clinical development and R&D teams

  • Healthcare consultants and analysts

  • Competitive intelligence and forecasting teams

  • Public health and infectious disease organizations

  • Strategic partnership and M&A advisory professionals

How Companies Use This Report

Pharmaceutical companies developing HIV therapies may use this report to assess market competition, benchmark pipeline strength, and evaluate emerging treatment opportunities across the global HIV therapeutics landscape.

Commercial strategy and licensing teams may use the analysis to identify promising late-stage products, assess unmet patient needs, and evaluate long-term revenue opportunities across treatment and prevention segments.

Healthcare investors and business development professionals may also use the report to evaluate commercial potential, competitive positioning, and innovation trends influencing the future HIV market.

In addition, R&D and clinical strategy teams may use the insights to benchmark evolving therapy approaches, assess future market gaps, and better understand treatment adoption patterns across the 7MM.

Key Highlights

Report deliverables include a Word report and an Excel-based forecast model

Forecast includes the 7 major markets (7MM)

Forecast covers the period 2023-2033

Reasons to Buy

Benchmark Against Leading HIV Therapeutics Companies

The report helps benchmark pipeline innovation, treatment positioning, therapy adoption trends, pricing strategies, and commercial performance across the HIV therapeutics market.

Moreover, it provides comparative insight into marketed therapies, late-stage pipeline assets, and future treatment approaches, helping organizations evaluate competitive threats and identify strategic growth opportunities more effectively.

Built on Trusted GlobalData Pharma Intelligence

Built using proprietary pharmaceutical datasets, epidemiology analysis, forecasting models, and competitive intelligence frameworks, this report combines scientific, clinical, and commercial analysis into a comprehensive strategic resource.

Trusted by pharmaceutical companies, biotech innovators, healthcare investors, and infectious disease strategy teams, and supported by expert analyst insights, the report provides a reliable view of the evolving HIV therapeutics market.

Act Now to Capture Opportunities in the HIV Therapeutics Market

As advances in ART, long-acting injectables, and preventive therapies continue transforming HIV management, the market is expected to evolve steadily through 2033.

Organizations that closely monitor treatment innovation, pipeline developments, epidemiology trends, and competitive dynamics may be better positioned to strengthen commercial strategies, identify emerging opportunities, and support long-term growth within the global HIV therapeutics industry.

Gilead
Janssen
Merck
ViiV Healthcare
GSK
AbbVie
Theratechnologies
Roche
Cytodyn

Table of Contents

List of Contents

List of Tables

List of Figures

1 HIV: Executive Summary

1.1 Summary of changes

1.2 Key metrics for HIV

1.3 HIV market to reach $30.6 billion by 2033

1.4 Gilead Sciences to remain leading player in the HIV space

1.5 Despite major advances in ART, significant unmet needs remain

1.6 Pipeline STRs will not surpass Biktarvy in terms of commercial success

1.7 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Clinical stages of HIV infection

3.3 Prognosis and quality of life

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.3.1 Total prevalence of HIV

4.3.2 Diagnosed prevalence of HIV

4.3.3 Diagnosed incidence of HIV

4.4 7MM forecast methodology

4.4.1 Sources

4.4.2 Sources not used

4.4.3 Forecast assumptions and methods

4.4.4 Total prevalent cases of HIV

4.4.5 Diagnosed prevalent cases of HIV

4.4.6 Diagnosed prevalent cases of HIV with hepatitis B virus/hepatitis C virus coinfection

4.4.7 Diagnosed prevalent cases of HIV on antiretroviral treatment

4.4.8 Diagnosed incident cases of HIV

4.4.9 Prophylactic population on pre-exposure prophylaxis

4.4.10 Prophylactic population on post-exposure prophylaxis

4.5 Epidemiological forecast for HIV (2023–33)

4.5.1 Total prevalent cases of HIV

4.5.2 Diagnosed prevalent cases of HIV

4.5.3 Age-specific diagnosed prevalent cases of HIV

4.5.4 Sex-specific diagnosed prevalent cases of HIV

4.5.5 Diagnosed prevalent cases of HIV with coinfection

4.5.6 Diagnosed prevalent cases of HIV on antiretroviral treatment

4.5.7 Diagnosed incident cases of HIV

4.5.8 Age-specific diagnosed incident cases of HIV

4.5.9 Sex-specific diagnosed prevalent cases of HIV

4.5.10 Prophylactic population on pre-exposure prophylaxis

4.5.11 Prophylactic population on post-exposure prophylaxis

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Better prevention and testing, and earlier diagnosis

7.3 Improvements to mental health, social and ancillary care services

7.4 More affordable and accessible prophylactic and therapeutic options

7.5 Addressing drug resistance

8 R&D Strategies

8.1 Overview

8.1.1 Stem cell transplants leading to HIV remission

8.1.2 Long-acting therapy options for prevention

8.1.3 Germline-targeting strategies in HIV vaccine development

8.1.4 Two-drug single-tablet regimens

8.2 Clinical trials design

8.2.1 Inclusion of underrepresented populations

8.2.2 Adoption of innovative trial methodologies

8.2.3 Emphasis on long-acting prevention and treatment modalities

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets (7MM)

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs interviewed for this report

13.4.1 KOLs

13.5 Primary research – prescriber survey

13.6 About the Authors

13.6.1 Analysts

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Epidemiology Reviewers

13.6.5 Vice President of Disease Intelligence and Epidemiology

13.6.6 Global Head of Pharma Research, Analysis and Competitive Intelligence

About GlobalData

Contact Us

Table

Table 1: Summary of changes to the Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast and Market Analysis Report

Table 2: HIV – key metrics in the 7MM

Table 3: Symptoms and comorbidities of acute, chronic, and advanced stages of HIV infection

Table 4: Risk factors and comorbidities for HIV

Table 5: Treatment guidelines for HIV

Table 6: Overview of key HIV marketed therapies

Table 7: Top 10 deals by value, 2015–25

Table 8: HIV market – global drivers and barriers, 2023–33

Table 9: Key events impacting sales for HIV in the US, 2023–33

Table 10: HIV market – drivers and barriers in the US, 2023–33

Table 11: Key events impacting sales for HIV in the 5EU, 2023–33

Table 12: HIV market – drivers and barriers in the 5EU, 2023–33

Table 13: Key events impacting sales for HIV in Japan, 2023–33

Table 14: HIV market – drivers and barriers in Japan, 2023–33

Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Global sales forecast by country for HIV in 2023 and 2033

Figure 2: Analysis of the company portfolio gap in HIV during the forecast period

Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for HIV during the forecast period

Figure 4: 7MM, total prevalence of HIV, both sexes, %, all ages, 2013–33

Figure 5: 7MM, diagnosed prevalence of HIV, both sexes, %, all ages, 2013–33

Figure 6: 7MM, diagnosed incidence of HIV, both sexes, %, all ages, 2013–33

Figure 7: 7MM, sources used to forecast the total prevalent cases of HIV

Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of HIV

Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of HIV with HBV or HCV coinfection

Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of HIV on ART

Figure 11: 7MM, sources used to forecast the diagnosed incident cases of HIV in the 7MM

Figure 12: 7MM, sources used to forecast the population on PrEP in the 7MM

Figure 13: 7MM, sources used to forecast the PEP coverage in the 7MM

Figure 14: 7MM, total prevalent cases of HIV, N, both sexes, all ages, 2023

Figure 15: 7MM, diagnosed prevalent cases of HIV, N, both sexes, all ages, 2023

Figure 16: 7MM, diagnosed prevalent cases of HIV by age, N, both sexes, 2023

Figure 17: 7MM, diagnosed prevalent cases of HIV by sex, N, all ages, 2023

Figure 18: 7MM, diagnosed prevalent cases of HIV with HBV/HCV coinfection, N, both sexes, all ages, 2023

Figure 19: 7MM, diagnosed prevalent cases of HIV on ART, N, both sexes, all ages, 2023

Figure 20: 7MM, diagnosed incident cases of HIV, N, both sexes, all ages, 2023

Figure 21: 7MM, diagnosed incident cases by age, N, both sexes, 2023

Figure 22: 7MM, diagnosed incident cases of HIV by sex, all ages, 2023

Figure 23: 7MM, prophylactic population on PrEP, N, both sexes, all ages, 2023

Figure 24: 7MM, prophylactic population on PEP, N, both sexes, all ages, 2023

Figure 25: Unmet needs and opportunities in HIV

Figure 26: Overview of the development pipeline in HIV

Figure 27: Key late-stage trials for the promising Phase III pipeline agents that GlobalData expects to be licensed for HIV in the 7MM during the forecast period

Figure 28: Competitive assessment of the late-stage STR drugs benchmarked against the SOC, Biktarvy

Figure 29: Analysis of the company portfolio gap in HIV during the forecast period

Figure 30: Global (7MM) sales forecast by country for HIV in 2023 and 2033

Figure 31: Sales forecast by class for HIV in the US in 2023 and 2033

Figure 32: Sales forecast by class for HIV in the 5EU in 2023 and 2033

Figure 33: Sales forecast by class for HIV in Japan in 2023 and 2033

Human Immunodeficiency Virus (HIV) Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

Most Popular
$35,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Human Immunodeficiency Virus (HIV) Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Human Immunodeficiency Virus (HIV) Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 in real time.

  • Access a live Human Immunodeficiency Virus (HIV) Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more